This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Cerus Submits Investigational Device Exemption (IDE) Supplement To FDA For Phase III INTERCEPT Red Blood Cell Study

Cerus Corporation (NASDAQ: CERS) announced today that it has submitted an IDE supplement to the U.S. Food and Drug Administration (FDA) for the company’s proposed Phase III trial of the INTERCEPT Blood System for red cells in patients receiving chronic red cell transfusion support for sickle cell disease (SCD) or thalassemia.

“We look forward to working with FDA to finalize the Phase III study protocol to support U.S. licensure of INTERCEPT red cells for support of patients with chronic anemia,” commented Dr. Laurence Corash, Cerus’ chief medical officer. “Chronically transfused patients are at increased risk both from newly emerging pathogens, such as dengue virus, and from known infectious agents, such as Babesia, for which there are no currently licensed tests. Pathogen inactivation of red cells offers a potential new treatment option for this vulnerable patient population, who may face lifetime exposure to blood transfusion.”

The proposed trial design includes approximately 400 patients, who would receive transfusions of INTERCEPT or control red cells for treatment of sickle cell disease or thalassemia. Proposed endpoints of the study are designed to assess both the efficacy and safety of INTERCEPT red cells. FDA has provided guidance that an approximately 60 red cell unit paired in vitro study and an additional Phase I recovery and survival study using the final clinical disposable sets and reagents in healthy subjects will be required prior to initiation of the proposed Phase III trial. These prerequisite studies may need to be finished and the data submitted prior to the FDA’s review of the Phase III protocol supplement filed in the IDE. Previous discussions with the FDA indicated that Cerus’ Phase III protocol could be reviewed under a Special Protocol Assessment (SPA), but upon receipt of the application the FDA amended its position and requested use of the IDE route. The proposed Phase III study size and endpoints in the IDE supplement are identical to those previously planned for SPA review.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 17,689.86 -56.12 -0.32%
S&P 500 2,103.84 -4.79 -0.23%
NASDAQ 5,128.2810 -0.5040 -0.01%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs